Cantabio's therapeutic program on Alzheimer’s and Parkinson's disease was featured as part of an article titled "Drugging the Disorderome" in the October 2017 issue of The Scientist magazine. The article reviewed the potential for developing therapeutics for historically difficult to target intrinsically disordered proteins, the new techniques that can allow the screening for drug candidates to target them and highlighted Cantabio's expertise in this area.
Cantabio in the News
Article by Innotéka magazine, an interview with Cantabio's CEO, Dr Gergely Tóth, describing the company's innovative approach to tacking the diseases by tackling the root causes of protein aggregation and oxidative stress.
Cover Story by Biocentury Innovations, describing how Cantabio is using an alternative approach, enhancing the function of the DJ-1 protein, rather than the more common dopamine compensation strategy. This means developing a disease-modifying therapy instead of treating only the disease's symptoms. Mentioning also our pharmacological chaperone approach in Alzheimer's targeting B-amyloid and tau.
Interview with Dr. Gergely Tóth (founder and CEO), Dr. Thomas Sawyer (COO) regarding Cantabio's research and its preclinical development programs published in U.S. Pharma Newsletter.